Statin reduces triglyceride level via activating PPARα and upregulating apolipoprotein A5 in hypertriglyceridemic rats / 中华内分泌代谢杂志

ABSTRACT

Objective To explore the potential role of apolipoprotein A5 (ApoA5) on the hypertriglyceridemia (HTG)-lowering effects of statin. Methods Twenty-four Sprague-Dawley rats were assigned to 3 groups(1)control group, with no special treatment. (2) HTG group, treated with 10% fructose water for 6 weeks. (3) statin 4 weeks. Body weight, fasting plasma lipids, and the hepatic expressions of ApoA5 and PPARα were determined. In separate in vitro experiments, the effects of atorvastatin on triglyceride (TG) and the expressions of ApoA5 and PPARα in HepG2 cells were tested. Results (1) Plasma TG was higher in HTG group than in controls group, which was significantly reduced in statin group (both P ＜ 0. 05). (2) Rat hepatic ApoA5expression in HTG group was significantly lower than in control group and it was significantly higher in statin group than in HTG group (both P＜0. 05). (3) Similarly, rat PPARα mRNA expression in HTG group was lower than in control group and it was higher in statin group than in HTG group (both P ＜ 0.05). (4) Statin significantly upregulated the expressions of ApoA5 and PPARα and decreased TG in HepG2 cells, which was blocked in the presence of PPARα inhibitor. Conclusion Upregulation of ApoA5 expression contributes to TG lowering effect of statin via PPARα signaling pathway.